GlassScriptPhysician profile
Beth Anne Seiler
NPI 1134156391
$4,912.57
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,141 · 2020: $1,254 · 2021: $1,517.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $882.66 | 2019-2021 | |
| Glaxosmithkline, LLC. | $591.95 | 2019-2021 | |
| Genzyme Corporation | $574.07 | 2019-2021 | |
| Pfizer INC. | $470.00 | 2019-2021 | |
| Optinose US, INC. | $269.55 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $261.28 | 2019-2020 | |
| Pharming Healthcare, INC. | $244.52 | 2019-2021 | |
| Grifols USA, LLC | $236.34 | 2019-2021 | |
| Csl Behring | $179.05 | 2019-2021 | |
| Alk-Abello, INC | $155.18 | 2019-2021 | |
| Kaleo, INC. | $155.18 | 2019-2021 | |
| Genentech USA, INC. | $138.54 | 2019-2021 | |
| Mylan Specialty L.P. | $120.92 | 2020 | |
| Covis Pharma Gmbh | $118.92 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $114.48 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $105.05 | 2019 | |
| Phadia US INC. | $86.04 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $74.39 | 2019 | |
| Biocryst US Sales Co., LLC | $42.12 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $28.68 | 2021 | |
| Shire North American Group INC | $18.01 | 2019 | |
| Amgen INC. | $17.37 | 2020 | |
| Sanofi-Aventis U.S. LLC | $14.84 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.43 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Seiler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.